[go: up one dir, main page]

AU2001263264A1 - Tablets and methods for modified release of hydrophilic and other active agents - Google Patents

Tablets and methods for modified release of hydrophilic and other active agents

Info

Publication number
AU2001263264A1
AU2001263264A1 AU2001263264A AU6326401A AU2001263264A1 AU 2001263264 A1 AU2001263264 A1 AU 2001263264A1 AU 2001263264 A AU2001263264 A AU 2001263264A AU 6326401 A AU6326401 A AU 6326401A AU 2001263264 A1 AU2001263264 A1 AU 2001263264A1
Authority
AU
Australia
Prior art keywords
tablets
hydrophilic
methods
active agents
modified release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001263264A
Inventor
James Shunnan Chu
Joseph A. Fix
Yisong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharma Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Technologies Inc filed Critical Yamanouchi Pharma Technologies Inc
Publication of AU2001263264A1 publication Critical patent/AU2001263264A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001263264A 2000-05-19 2001-05-18 Tablets and methods for modified release of hydrophilic and other active agents Abandoned AU2001263264A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/599,102 US6419954B1 (en) 2000-05-19 2000-05-19 Tablets and methods for modified release of hydrophilic and other active agents
US09/599,102 2000-05-19
PCT/US2001/016137 WO2001089483A1 (en) 2000-05-19 2001-05-18 Tablets and methods for modified release of hydrophilic and other active agents

Publications (1)

Publication Number Publication Date
AU2001263264A1 true AU2001263264A1 (en) 2001-12-03

Family

ID=24398223

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001263264A Abandoned AU2001263264A1 (en) 2000-05-19 2001-05-18 Tablets and methods for modified release of hydrophilic and other active agents

Country Status (6)

Country Link
US (2) US6419954B1 (en)
EP (1) EP1286662A4 (en)
JP (1) JP4853695B2 (en)
AU (1) AU2001263264A1 (en)
CA (1) CA2409292C (en)
WO (1) WO2001089483A1 (en)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP4806507B2 (en) 1999-10-29 2011-11-02 ユーロ−セルティーク エス．エイ． Controlled release hydrocodone formulation
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
WO2002002081A1 (en) * 2000-07-05 2002-01-10 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and methods of using same
MXPA03003895A (en) 2000-10-30 2003-07-28 Euro Celtique Sa Controlled release hydrocodone formulations.
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
CN1212126C (en) * 2002-07-09 2005-07-27 中国科学院长春应用化学研究所 Nano-hydroxyapatite calcium supplement
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
FR2845289B1 (en) * 2002-10-04 2004-12-03 Ethypharm Sa SPHEROIDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS.
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
CA2503284A1 (en) * 2002-10-24 2004-05-06 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
JP2004307398A (en) * 2003-04-07 2004-11-04 National Institute For Materials Science Drug-encapsulated multilayer fine particles
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US20050013897A1 (en) * 2003-07-14 2005-01-20 Meyer John M. Long-lasting crustacean bait for use in traps and method of making the same
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
CA2536487C (en) * 2003-09-12 2011-10-25 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
EP1675619A4 (en) * 2003-09-29 2010-10-06 Palmetto Pharmaceuticals Llc Sustained release l-arginine formulations and methods of manufacture and use
US7051606B2 (en) * 2004-01-30 2006-05-30 Andrx Labs Llc Dosage form holder device and methods for immersion testing
JP2005306778A (en) * 2004-04-21 2005-11-04 Basf Ag Sustained-release formulation and method for producing the same
KR20070013316A (en) * 2004-05-21 2007-01-30 알자 코포레이션 Formulations for Multi-Drug Form Delivery
ES2653568T3 (en) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Drug formulations for abuse prevention
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
EP2594259A1 (en) 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
US8309128B2 (en) * 2005-06-10 2012-11-13 Pierre Fabre Medicament Stabilized milnacipran formulation
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
UA95093C2 (en) * 2005-12-07 2011-07-11 Нікомед Фарма Ас Method for the preparation of calcium-containing compound
RS53624B1 (en) * 2006-03-16 2015-04-30 Euro-Celtique S.A. PHARMACEUTICAL SFEROIDS
ES2378573T3 (en) 2006-03-16 2012-04-16 Tris Pharma, Inc. Modified release formulations containing ion exchange drug-resin complexes
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8202538B2 (en) * 2006-06-26 2012-06-19 Capricorn Pharma, Inc. Orally disintegrating layered compositions
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
JP5245175B2 (en) * 2006-11-13 2013-07-24 杏林製薬株式会社 Method for producing sustained release tablet
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
ES2557881T3 (en) * 2007-04-06 2016-01-29 Koninklijke Douwe Egberts B.V. Procedure for the manufacture of a coffee tablet and coffee tablet for the preparation of coffee obtained by said method
US8273798B2 (en) * 2007-06-04 2012-09-25 Shear Kershman Laboratories Tamper resistant lipid-based oral dosage form for opioid agonists
JP5965583B2 (en) 2007-08-13 2016-08-10 インスピリオン デリバリー テクノロジーズ エルエルシー Abuse resistant pharmaceutical composition, method of use and preparation
US20100221335A1 (en) * 2007-08-31 2010-09-02 Daiichi Sankyo Company, Limited Sustained-release preparation and method for producing the same
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
MX2010008138A (en) 2008-01-25 2010-08-10 Gruenenthal Gmbh Pharmaceutical dosage form.
TWI524904B (en) 2008-05-09 2016-03-11 歌林達股份有限公司 A method for preparing a solid dosage form for medicine, especially a tablet, and a method for preparing a solid dosage form, especially a pre-load of a tablet
US7662858B2 (en) 2008-05-23 2010-02-16 Aaipharma, Inc. Method of treating post-surgical acute pain
US8420700B1 (en) * 2008-06-04 2013-04-16 James M. Bausch Tamper resistant lipid-based oral dosage form for sympathomimetic amines
US20110195121A1 (en) * 2008-06-19 2011-08-11 Seshni Sewlall chronotherapeutic pharmaceutical dosage form
TWI478712B (en) 2008-09-30 2015-04-01 Astellas Pharma Inc Pharmaceutical composition for modified release
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
EP2456425B1 (en) 2009-07-22 2015-10-21 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opioids
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
ES2665467T3 (en) 2010-03-29 2018-04-25 Astellas Pharma Inc. Modified Release Pharmaceutical Composition
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2011143120A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholres i stant metoprolol - containing extended - release oral dosage forms
EP2611426B1 (en) 2010-09-02 2014-06-25 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
KR20130137627A (en) 2010-09-02 2013-12-17 그뤼넨탈 게엠베하 Tamper resistant dosage form comprising an anionic polymer
WO2012056471A2 (en) * 2010-10-24 2012-05-03 Shasun Pharmaceuticals Limited Novel process for preparing dexibuprofen ready to compress granules
DK2826467T3 (en) 2010-12-22 2017-10-16 Purdue Pharma Lp INCLUDED, MANIPULATION-PROPOSED SLOW-DELIVERY DOSAGE FORMS
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
AU2012253667B2 (en) 2011-05-10 2017-06-01 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
KR20140053159A (en) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 Tamper-resistant tablet providing immediate drug release
CN103857386A (en) 2011-07-29 2014-06-11 格吕伦塔尔有限公司 Tamper-resistant tablet providing immediate drug release
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PT2838512T (en) 2012-04-18 2018-11-09 Gruenenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9717741B2 (en) 2012-10-11 2017-08-01 Anaplasi Pharmaceuticals Llc Method and compositions for treating psoriasis
WO2014058427A1 (en) 2012-10-11 2014-04-17 Anaplasi Pharmaceuticals Llc Method and compositions for treating psoriasis
HK1218392A1 (en) 2013-02-05 2017-02-17 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20140275150A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014273226B2 (en) 2013-05-29 2019-06-27 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
EP3019157A1 (en) 2013-07-12 2016-05-18 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
CN105934241B (en) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 Preparation of powdered pharmaceutical composition by cryogenic grinding
CN106572980A (en) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 Tamper resistant immediate release capsule formulation comprising tapentadol
MX2016015417A (en) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping.
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
MX2017007493A (en) 2014-12-17 2018-01-26 Empros Pharma Ab A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders.
US20160310429A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CA3008754A1 (en) * 2015-12-17 2017-06-22 MIZRAHI AKSIYOTE, Aldo Adolfo System for transferring mass with the capturing of solids via the induction of an electromagnetic field
RU2718906C2 (en) 2016-01-20 2020-04-15 Теравида, Инк. Methods and compositions for treating hyperhidrosis
EP3257574A1 (en) * 2016-06-15 2017-12-20 Clariant International Ltd Method for producing a particle-shaped material
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US10702495B2 (en) 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
US10874741B2 (en) 2017-08-28 2020-12-29 Spectrix Therapeutics, LLC Compound to treat Sjogren's syndrome
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
WO2019070581A1 (en) * 2017-10-02 2019-04-11 Purdue Pharma L.P Pharmaceutical compositions comprising delayed release gelling agent compositions
WO2020227319A1 (en) 2019-05-06 2020-11-12 Spinart, LLC Formulations and methods for preparing stable cosmetic compositions
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
EP3750528A1 (en) 2019-06-11 2020-12-16 Nexien Biopharma, Inc. Compositions for treating dystrophies and myotonia
EP4284347A1 (en) 2021-01-28 2023-12-06 Galvita AG Solid pharmaceutical compositions and methods of producing the same
EP4311543A1 (en) 2022-07-27 2024-01-31 Galvita AG Methods for loading template inverted carriers
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE575775A (en) * 1958-02-18
GB1598458A (en) * 1977-04-01 1981-09-23 Hoechst Uk Ltd Tableting of microcapsules
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
DE3527687A1 (en) * 1985-08-01 1987-02-12 Siemens Ag MAGNETIC COUPLING WITH INTEGRATED MAGNETIC BEARING RELIEF
JPS62120315A (en) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd Production of sustained release tablet
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
CA1316110C (en) * 1987-02-27 1993-04-13 Peter Lloyd Oren Sustained release matrix formulations
US4925675A (en) * 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
NZ255579A (en) 1992-09-18 1996-03-26 Yamanouchi Pharma Co Ltd Sustained release hydrogel pharmaceutical formulation
US5322655A (en) 1993-02-19 1994-06-21 Thomas Engineering, Inc. Method for monitoring and controlling the weights of each layer of a multilayer tablet
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5676972A (en) * 1995-02-16 1997-10-14 The University Of Akron Time-release delivery matrix composition and corresponding controlled-release compositions
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
AU5200098A (en) * 1996-11-01 1998-05-29 Ilex Oncology, Inc. Sustained release formulation containing dfmo
WO1998056359A2 (en) 1997-06-13 1998-12-17 Roland Bodmeier Compounds which delay the release of active substances
DE19747261A1 (en) * 1997-10-25 1999-04-29 Bayer Ag Single-chamber osmotic pharmaceutical release system
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents

Also Published As

Publication number Publication date
WO2001089483A9 (en) 2003-03-06
CA2409292A1 (en) 2001-11-29
EP1286662A1 (en) 2003-03-05
US6419954B1 (en) 2002-07-16
WO2001089483A1 (en) 2001-11-29
US20030108602A1 (en) 2003-06-12
EP1286662A4 (en) 2009-08-05
JP2003534269A (en) 2003-11-18
CA2409292C (en) 2008-05-13
JP4853695B2 (en) 2012-01-11

Similar Documents

Publication Publication Date Title
AU2001263264A1 (en) Tablets and methods for modified release of hydrophilic and other active agents
AU2002243277A1 (en) Methods and compositions for encapsulating active agents
AU2001253479A1 (en) Targeted therapeutic agent release devices and methods of making and using the same
AU2003213020A1 (en) Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AU2599501A (en) Device and active component for inhibiting formation of thrombus-inflammatory cell matrix
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
AU2466099A (en) Pharmaceutically active compounds and methods of use thereof
AU2001234587A1 (en) Distributed active knowledge and process base
AU2093101A (en) Compositions for efficient release of active ingredients
AU2002338806A1 (en) Pharmaceutical combinations of pde-v inhibitors and other agents
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
AU2001241729A1 (en) Protected forms of pharmacologically active agents and uses therefor
AU2208401A (en) Inhibitors of complement activation, their preparation and use
IL142375A0 (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
AU6386801A (en) System for the release of active ingredients
AU2003228658A1 (en) Conjugates of membrane translocating agents and pharmaceutically active agents
AU2001248336A1 (en) Controlled release oral solid forms containing mesalazine as active agent
AU4112401A (en) Hydrophilic member and method for manufacture thereof
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
HUP0002719A3 (en) Controlled release pharmaceutical preparation with ace inhibitor as active agent
AU2001232948A1 (en) Controlled release of drugs
AU2002221273A1 (en) Delayed and sustained release formulations and method of use thereof
AU5820900A (en) Capsule for the controlled release of active substances
AU2001230898A1 (en) Formulations and methods for administration of pharmacologically or biologicallyactive compounds
AU2002351388A1 (en) Methods and compositions for controlled release of drugs